GlaxoSmithKline has withdrawn its European application for Votrient for use in ovarian cancer, after phase III trials failed to prove the drug's effectiveness. Votrient (pazopanib) is already ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback